Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2019 | Identifying predictive markers for checkpoint inhibitor response in kidney cancer

Tian Zhang • 15 Feb 2019
GU Cancers 2019
Genitourinary Cancer Kidney Cancer Checkpoint Inhibitors Nivolumab

Tian Zhang, MD, of Duke Cancer Center, Durham, NC, discusses the role of sequencing in identifying genomic mutations that correlate with immunotherapy response in kidney cancer patients. Speaking at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA, Dr Zhang reports that results from sequencing can be used to help choose combination treatment options to pair with immunotherapy.

More from Tian Zhang

2:05
STARTAR: ADT with apalutamide, radiation therapy and docetaxel in prostate cancer
Tian Zhang • 2 Jun 2023
2:19
What are the latest in ADCs for prostate and bladder cancer?
Tian Zhang • 2 Jun 2023
1:14
Optimizing outcomes in PSA recurrent prostate cancer
Tian Zhang • 2 Jun 2023
1:06
Key trials in kidney cancer at ASCO GU 2023
Tian Zhang • 17 Feb 2023

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals